Other Name for Tirzepatide: Mounjaro, Zepbound, and More

Tirzepatide's other name is Mounjaro or Zepbound, depending on why it was prescribed. Tirzepatide is the nonproprietary (generic-style) name of the active ingredient, while Mounjaro and Zepbound are the two FDA-approved brand names for that same molecule in the United States. No FDA-approved generic version of tirzepatide is sold in the US.

Two prescriptions with different brand names can therefore contain the exact same drug.

Every Name Used for Tirzepatide

Tirzepatide shows up under several labels in prescribing information, pharmacy systems, and online marketplaces. Only two of those names refer to FDA-approved medicines.

Tirzepatide is the name used in scientific journals, FDA labeling, and international drug directories. LY3298176 is the internal code Eli Lilly used during clinical trials, and it never appears on a prescription.

Why One Molecule Has Two Brand Names

US regulators approve a drug for a specific indication, and a company may market the same molecule under a new brand name when the approved use changes. Eli Lilly launched tirzepatide as Mounjaro in May 2022 for type 2 diabetes. In November 2023, the same molecule was approved as Zepbound for chronic weight management in adults with obesity or overweight plus at least one weight-related condition.

Coverage for tirzepatide for sleep apnea expanded in December 2024, when Zepbound became the first FDA-approved drug for moderate-to-severe obstructive sleep apnea in adults with obesity. That decision added a third indication but no third brand name.

Outside the United States, the naming is simpler. The European Medicines Agency authorized Mounjaro for weight management in 2024, so the same brand name covers both diabetes and obesity across much of Europe and the UK. In Japan and several other markets, tirzepatide is also sold as Mounjaro.

What the Name on Your Label Tells You

The tirzepatide brand name on your prescription usually reveals the reason it was written. Mounjaro prescriptions are generally issued for blood sugar control in type 2 diabetes. Zepbound prescriptions are written for tirzepatide for weight loss or for sleep apnea in adults with obesity.

People who ask what is tirzepatide for often get a one-word answer — diabetes or weight loss — but the research pipeline is broader. Investigators are studying the molecule in fatty liver disease, heart failure with preserved ejection fraction, and knee osteoarthritis pain. None of those uses are approved today.

Insurance coverage follows the label, not the molecule. Many US plans cover Mounjaro for diabetes while requiring prior authorization, a documented BMI, or step therapy for Zepbound.

Names That Are Not Tirzepatide

Several drug names get mixed up with tirzepatide because they belong to the same class of incretin-based medicines.

• Semaglutide — sold as Ozempic, Wegovy, and Rybelsus. Semaglutide targets GLP-1 only, while tirzepatide targets both GIP and GLP-1.
• Liraglutide — sold as Victoza and Saxenda.
• Dulaglutide — sold as Trulicity.
• Retatrutide — an investigational triple agonist that is not FDA-approved.

Search interest in tirzepatide vs semaglutide which is better for weight loss reflects how often the two are confused. They are different molecules with different clinical trial results, and the right choice depends on medical history, side effects, and insurance coverage.

Misspellings such as "trizepatide," "tirzepetide," and "terzepatide" are also common in search bars. None of them describe a separate medication.

Unapproved and Compounded Versions

During supply shortages, some compounding pharmacies sold products labeled "compounded tirzepatide." The FDA has stated that these products are not approved and has received reports of dosing errors and adverse events tied to them.

Sellers may also use names like "tirzepatide peptide," "tirzepatide sodium," or "research-grade tirzepatide." Those labels typically signal that the product is not intended for human use.

Authentic Mounjaro and Zepbound arrive in single-dose pens or vials from Eli Lilly with a validated lot number, expiration date, and manufacturer packaging.

Safety and How to Verify What You Have

Both approved products carry a boxed warning about thyroid C-cell tumors observed in rodents. Neither should be used by anyone with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.

If you are unsure which version you have, work through these checks:

1. Read the active ingredient line — it should say tirzepatide.
2. Confirm the brand name is one of the two FDA-approved names.
3. Check the manufacturer, lot number, and expiration date on the carton.
4. Ask a pharmacist to confirm the pen strength against your prescriber's titration plan.
5. Report suspected counterfeit or unapproved products to the FDA.

Common side effects include nausea, vomiting, diarrhea, constipation, and injection-site reactions. Talk with a healthcare professional before starting, stopping, or switching between brand names, and never change a dose based on what a product calls itself.